Huntington disease (HD) is an inherited, autosomal dominant, neurodegenerative disorder with limited treatment options. Prior to motor symptom onset or neuronal cell loss in HD, levels of the type 1 cannabinoid receptor (CB 1 ) decrease in the basal ganglia. Decreasing CB 1 levels are strongly correlated with chorea and cognitive deficit. CB 1 agonists are functionally selective (biased) for divergent signaling pathways. In this study, six cannabinoids were tested for signaling bias in in vitro models of medium spiny projection neurons expressing wild-type (STHdh Q7/Q7 ) or mutant huntingtin protein (STHdh Q111/Q111
Introduction
Huntington Disease. Expression of mutant huntingtin protein (mHtt) causes a myriad of molecular and cellular changes that ultimately cause progressive worsening of the symptoms of Huntington disease (HD). Early in HD progression, levels of type 1 cannabinoid receptor (CB 1 ) mRNA and protein decrease in medium spiny projection neurons of the caudate and putamen (Denovan-Wright and Robertson, 2000; Glass et al., 2000; Van Laere et al., 2010) . CB 1 transcription is inhibited by mHtt (McCaw et al., 2004; Laprairie et al., 2013) . The reduction in CB 1 and loss of CB 1 function have been shown to contribute to the cognitive, behavioral, and motor deficits of HD pathology in animal models of HD (Blázquez et al., 2011; 2015; Chiarlone et al., 2014) . Furthermore, rescue of CB 1 gene expression in the striatum using viral transduction prevents the loss of excitatory synaptic markers and reduces dendritic spine loss in animal models of HD (Naydenov et al., 2014) . The benefit of adenoassociated viral CB 1 delivery in HD provides strong proof for the concept of treating HD through enhancing CB 1 function. However, gene-based therapies specifically for CB 1 or other single alterations in gene expression, will probably not be used clinically for HD in the near future because of the invasive nature of delivery and because the potential adverse effects of gene therapy are still being investigated. The more effective gene-based therapies for HD will target the underlying cause of the disease, the mHtt gene and encoded protein, and not secondarily lost cellular components (Kumar et al., 2015) . In contrast, pharmacological strategies aimed at elevating CB 1 levels and/or signaling through remaining pool of CB 1 receptors has significant therapeutic potential for the treatment and management of HD.
Pharmacological Targeting of CB 1 . CB 1 is activated by cannabinoids, which are a structurally diverse group of ligands that includes endogenously occurring cannabinoids (endocannabinoids) such as anandamide (AEA) and 2-arachidonoylglycerol (2-AG), phytocannabinoids from Cannabis sativa such as D 9 -tetrahydrocannabinol (THC), and synthetic cannabinoids such as CP55,940 (CP) and WIN55,212-2 (WIN) (Pertwee, 2008) . Activation of CB 1 in the brain results in inhibition of neurotransmitter release from presynaptic glutamatergic and GABAergic neurons and activation of prosurvival signaling cascades such as extracellular signal-regulated kinase (ERK) and protein kinase B (Akt) (Fernández-Ruiz, 2009 ). We have reported that AEA, and structurally related compounds, increase the expression of CB 1 via CB 1 through Ga i/o and Gbg signaling in a cell culture model expressing normal huntingtin (STHdh Q7/Q7 ) and cells expressing mHtt (STHdh Q111/Q111 ) . Importantly, this cell culture model endogenously expresses CB 1 and other components of the endocannabinoid system. Increasing levels of CB 1 improved neuronal viability in this cell culture model , lending further support to the strategy of enhancing signaling through the pool of CB 1 that are retained in the presence of mHtt and elevating CB 1 levels in these cells despite transcriptional repression via mHtt.
Not all cannabinoids increase CB 1 levels. THC and CP treatment promote b-arrestin-dependent CB 1 internalization and reduce CB 1 -dependent downstream signaling (Laprairie et al., 2014) . Functional selectivity (i.e., signaling bias) describes the receptor-and ligand-dependent enhancement of certain signal transduction pathways and the simultaneous diminution of other signal transduction pathways at a single receptor (Luttrell et al., 2015) . Functional selectivity occurs via a GPCR ligand that preferentially activates one effector (e.g., Ga i/o ) more potently and efficaciously than another (e.g., b-arrestin) through ligand-specific changes in GPCR conformation or dimerization with other GPCRs (Christopoulos, 2014) . Signaling bias could be exploited for enhancement of CB 1 function in HD, at the same time limiting detrimental adverse on-target effects (Laprairie et al., 2014) . Cannabinoids display signaling bias (Laprairie et al., 2014; Khajehali et al., 2015) . Endocannabinoids acting at CB 1 are Ga i/o -biased, whereas THC and CP are b-arrestinbiased in STHdh Q7/Q7 cells (Laprairie et al., 2014) . In this study, we wanted to determine how the bias of different classes of cannabinoid affected neuronal viability. We hypothesized that Ga i/o -biased cannabinoids improve neuronal viability, whereas b-arrestin-biased cannabinoids reduce-or have no effect oncell viability. The functional selectivity of six cannabinoids [AEA, 2-AG, THC, cannabidiol (CBD), WIN, and CP] between Ga i/o -, Ga s -, Ga q -, Gbg-, and b-arrestin pathways was examined in STHdh Q7/Q7 and STHdh Q111/Q111 cells and compared with cannabinoid-dependent changes in ATP level, g-aminobutyric acid (GABA) release, metabolic activity, and cell death.
Materials and Methods
Drugs. Drugs were dissolved in ethanol (THC) or DMSO [2-AG, 8-OH-DPAT (5HT 1A agonist), AEA, CP, CBD, gallein (Gbg inhibitor), haloperidol (D 2 antagonist), O-2050 (CB 1 antagonist), quinpirole (D 2 agonist), WAY-100,635 (5HT 1A antagonist), WIN] and diluted to final solvent concentrations of 0.1%. 2-AG, AEA, CP, CBD, O-2050, and WIN were purchased from Tocris Bioscience (Bristol, UK). 8-OH-DPAT, haloperidol, quinpirole, THC, and WAY-100,635 were purchased from Sigma-Aldrich (Oakville, ON, CAN). The Gbg modulator gallein was purchased from MilliporeSigma (Billerica, MA). Pertussis toxin (PTx) and Cholera toxin (CTx) (Sigma-Aldrich) were dissolved in dH 2 O (50 ng/ml) and added directly to the media 24 hours prior to cannabinoid treatment. Pretreatment of cells with PTx and CTx inhibits Ga i/o and Ga s , respectively (Milligan et al., 1989) . In the case of CTx, this occurs via downregulation of Ga s following ADPribosylation (Milligan et al., 1989; McKenzie and Milligan, 1991) . All experiments included a vehicle treatment control.
Cell Culture. STHdh Q7/Q7 and STHdh Q111/Q111 cells are derived from the conditionally immortalized striatal progenitor cells of embryonic day 14 C57BlJ/6 mice (Coriell Institute, Camden, NJ) (Trettel et al., 2000) . STHdh Q111/Q111 cells express exon 1 of the mutant human huntingtin gene containing 111 CAG repeats knocked into the mouse huntingtin locus (Trettel et al.., 2000) . STHdh Q7/Q7 and STHdh Q111/Q111 cells endogenously express CB 1 and dopamine D 2 receptor (Paoletti et al., 2008; Laprairie et al., 2014) . Cells were maintained at 33°C, 5% CO 2 in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 10 4 IU ml 21 penicillin/streptomycin, and 400 mg ml 21 geneticin. Cells were serum-deprived for 24 hours prior to experiments to promote differentiation (Trettel et al., 2000; Laprairie et al., 2014) . Plasmids and Transfection. Human CB 1 -green fluorescent protein 2 (GFP 2 ) C-terminal fusion protein was generated using the pGFP 2 -N3 plasmid (PerkinElmer, Waltham, MA), as described previously (Bagher et al., 2013) . Human arrestin2 (b-arrestin1)-Renilla luciferase II (Rluc) C-terminal fusion protein was generated using the pcDNA3.1 plasmid and provided by Dr. Denis J Dupré (Dalhousie University, NS). The GFP 2 -Rluc fusion construct, and Rluc plasmids have also been described (Bagher et al., 2013) . The Ga q dominant negative mutant [Glu 209 D Leu, Asp 277 D Asn (Q209L,D277N)] pcDNA3.1 plasmid was obtained from the cDNA Resource Center (Missouri S&T, Rolla, MO) (Lauckner et al., 2005) .
Cells were grown in six-well plates and transfected with 200 ng of the Rluc fusion plasmid and 400 ng of the GFP 2 fusion plasmid according to previously described protocols (Laprairie et al., 2014) using Lipofectamine 2000 according to the manufacturer's instructions (Invitrogen, Burlington, Canada). Transfected cells were maintained for 48 hours prior to experimentation. BRET 2 . Interactions between CB 1 and b-arrestin1 were quantified via BRET 2 (Packard BioScience Company, Meriden, CT) according to previously described methods (James et al., 2006; Laprairie et al., 2014) . Bioluminescence resonance energy transfer (BRET) efficiency (BRET Eff ) was determined such that Rluc alone was used to calculate BRET MIN and the Rluc-GFP 2 fusion protein was used to calculate BRET MAX using previously described methods (James et al., 2006) .
On-and In-Cell Western. On-Cell Western (LI-COR Biosciences, Lincoln, NE) analyses were completed as described previously (Laprairie et al., 2014) using primary antibody directed against N-CB 1 (1:500, cat. no. 101500; Cayman Chemical Company, Ann Arbor, MI). All experiments measuring CB 1 included an N-CB 1 blocking peptide (1:500) control, which was incubated with N-CB 1 antibody (1:500). Immunofluorescence observed with the N-CB 1 blocking peptide was subtracted from all experimental replicates. In-Cell Western (LI-COR Biosciences) analyses were conducted as described previously (Laprairie et al., 2014) . Primary antibody solutions were directed against: the amino terminus of CB 1 (N-CB 1 ) (1:500), phosphorylated (p)ERK1/2(Tyr205/185) (1:500), ERK1/2 (1:500), pCREB(S133) (1:500), cAMP response element-binding protein (CREB) (1:500), pPLCb3(S537) (1:500), PLCb3 (1:1000), pAkt (S473) (1:500), protein kinase B (Akt) (1:1000), or b-actin (1:2000; Santa Cruz Biotechnology, Dallas, TX). Secondary antibody solutions were: IR CW700dye or IR CW800dye (1:500; Rockland Immunochemicals, Pottstown, PA).
ATP Quantification, g-Aminobutyric Acid Enzyme-Linked Immunosorbent Assay, and Cell Viability Assays. The CellTiterGlo ATP quantification assay was used according to the manufacturer's Biased CB1 Signaling in Huntington Disease instructions (Promega, Madison, WI). The GABA enzyme-linked immunosorbent assay was conducted according to the manufacturer's instructions for mouse cell culture media (Novatein Biosciences, Boston, MA). GABA levels were reported as DGABA relative to GABA in vehicletreated cells. Viability assays [calcein-AM (cal-AM), ethidium homodimer-1 (EthD-1)] were conducted according to the manufacturer's instructions (Live/Dead Cytotoxicity Assay, Life Technologies, Burlington, Canada). Cal-AM fluorescence is an indicator of cellular esterase activity and mitochondrial respiration. Cal-AM fluorescence (460/510 nm) is reported as % esterase activity relative to vehicletreated STHdh Q7/Q7 cells (100%). EthD-1 fluorescence is an indicator of membrane permeability and cell death. EthD-1 fluorescence (530/620 nm) is reported as % membrane permeability relative to STHdh Q7/Q7 cells treated with 70% methanol for 30 minutes (100%). All measurements of viability (ATP, GABA, calcein-AM, EthD-1) were made 18 hours following cannabinoid treatment.
Statistical Analyses. All experiments were conducted alongside WIN as a reference ligand. Although it is often considered ideal to choose the endogenous receptor agonist as a reference ligand (Kenakin and Christopoulos, 2013) , WIN was chosen as a reference ligand for these studies because: 1) it is a widely used reference compound to study CB 1 -dependent signaling (Lauckner et al., 2005) ; 2) it acted as an agonist in all assays with nonsignificant differences in EC 50 observed between assays; and 3) we wanted to determine whether the two endogenous cannabinoids, AEA and 2-AG, were inherently biased either in wild-type (STHdh Q7/Q7 ) or mHtt-expressing (STHdh Q111/Q111 ) cells. Concentration-response curves for ERK, BRET 2 (CB 1 /b-arrestin1), CREB, phospholipase C (PLC)b3, and Akt are presented as % of WIN E max in STHdh Q7/Q7 cells (Griffin et al., 2007) . Concentration-response curves were fit to nonlinear regression with variable slope (four-parameter) model to determine pEC 50 and E max (Table 1) , or global nonlinear regression using the operational model (Black and Leff, 1983; Ehlert et al., 2011; Kenakin et al., 2012 ) (eq. 1) to estimate the transduction coefficient [logR (t/K A )], change in transducer coefficient relative to the reference ligand (DlogR), and bias factor (DDlogR) (Prism v. 5.0, GraphPad Software Inc., San Diego, CA), as indicated. In eq. (1) E is the response, E max is the maximal response, [A] is agonist concentration, n is transducer slope, t is agonist efficacy, and K A is the agonist's affinity for the receptor (Kenakin et al., 2012) . To obtain a global least-squares fit of the data to the operational model, n was constrained to 1 and logK A was shared between both STHdh Q7/Q7
and STHdh Q111/Q111 datasets and constrained to be greater than -15 (Griffin et al., 2007; Ehlert, 2015) . Relative activity (DlogR) was calculated in Prism as the difference between transduction coefficients [logR (t/K A )] values for two ligands, a "test" ligand, and a reference ligand (here WIN) as measured between sample-matched replicates (Kenakin et al., 2012 ) (eq. 2). In eq. (3) bias factor (i.e., log bias, DDlogR) is the difference between response 1 (R 1 ) and response 2 (R 2 ) (Kenakin et al., 2012) . All calculations of DDlogR are reported using pERK response (Ga i/o ) as R 1 . Statistical analyses were two-way analysis of variance (ANOVA) (Prism). Post-hoc analyses were performed using the Bonferroni test. Homogeneity of variance was confirmed using the Bartlett test. The level of significance was set to P , 0.01 where ANOVA was used or P , 0.05 where nonoverlapping confidence intervals (CI) were used to determine significance. Results are reported as the mean 6 S.E.M. from at least four independent experiments. b-arrestin1, Ga s -(CREB), Ga q -(PLCb3), and Gbg-dependent (Akt) signaling were measured. The coupling of each of these signaling pathways to CB 1 and their respective G proteins or b-arrestin1 has been tested previously (Laprairie et al., 2014) and is presented in (Supplemental Fig. 1 for a subset of cannabinoids. The agonist effects of all cannabinoids Fig. 1F ).
CB 1 is known to interact with b-arrestin1, which mediates receptor internalization, recycling, and degradation (SimSelley and Martin, 2002; Laprairie et al., 2014) . Unlike pERK, no differences in E max and pEC 50 were observed for b-arrestin1 assays. CP displayed higher pEC 50 and E max values than WIN, whereas no differences in pEC 50 and E max were observed between WIN, 2-AG, and THC, and AEA displayed lower E max values for b-arrestin1 recruitment in both cell lines (Table 1 ; Fig. 1 , B and G). CBD was not an agonist of b-arrestin1 recruitment. In the THC1CBD-treated cells, the E max and pEC 50 of BRET Eff were both reduced compared with THC-treated cells (Table 1) . These data are consistent with our previous finding that CBD is a negative allosteric modulator of THC-dependent effects at CB 1 (Laprairie et al., 2015) .
The observed E max and pEC 50 for pCREB (Ga S ) was not different in STHdh Q7/Q7 cells treated with WIN, CP, CBD, or THC1CBD, relative to STHdh Q111/Q111 cells (Table 1 ; Fig. 1 , C and H). AEA and 2-AG did not evoke a pCREB response. CP, CBD, and THC1CBD treatment resulted in E max values for pCREB higher than WIN treatment in both cell lines. pCREB pEC 50 and E max values were higher in CP-and CBD-treated cells compared with THC1CBD-treated cells (Table 1 ; Fig. 1 , C and H). Because CB 1 -dependent Ga S signaling is uncommon, this was examined further (see below).
CB 1 can also couple Ga q to modulate Ca 21 -and PLCb3-dependent signaling (Lauckner et al., 2005) . No differences were observed for PLCb3 phosphorylation between STHdh Q7/Q7 and STHdh Q111/Q111 cells (Table 1 ; Fig. 1 , D and I). pPLCb3 E max values were greater in WIN-, 2-AG-, and AEA-treated cells compared with CP-and THC-treated cells, with no change in pEC 50 (Table 1 ; Fig. 1, D and I) . CBD was not an agonist of PLCb3 phosphorylation.
In the case of pAkt (Gbg), no differences were observed between STHdh Q7/Q7 and STHdh Q111/Q111 cells ( Relative activity (DlogR) was calculated using WIN as the reference ligand (eq. 2). WIN was chosen as a reference ligand, rather than the endocannabinoids 2-AG and AEA (Kenakin and Christopoulos, 2013) , because it displayed activity in all assays, and we wanted to quantify the relative activity and bias of 2-AG and AEA in STHdh Q7/Q7 and STHdh Q111/Q111 cells. The DlogR for ERK response was lower in THC-and THC1CBD-treated cells compared with WIN (DlogR 5 0) ( Table 2 ). The DlogR for b-arrestin1 was lower in 2-AG-, AEA-, THC-, and THC1CBD-treated cells compared with WIN, and compared with the ERK response ( (Fig. 2, A-D) . Because CB 1 is classically considered a Ga i/o -coupled receptor (Kondo et al.., 1998; Lauckner et al., 2005) , all comparisons were made using Ga i/o -dependent ERK1/2 signaling (pERK) as DlogR 1 . On the basis of these data, CP evoked Ga S -and b-arrestin1-biased signaling compared with Ga i/o , and Ga i/obiased signaling compared with Ga q or Gbg in both cell types tested here (i.e., Ga S . b-arrestin1 . Ga i/o . Ga q . Gbg) (Fig.  2, A-D (Fig. 2, A-D) . Like 2-AG, AEA evoked Ga i/o -biased signaling compared with b-arrestin1 and Ga q (more so in STHdh Q111/Q111 cells), and Gbg-biased signaling compared with Ga i/o (in STHdh Q7/Q7 cells) (i.e., Gbg . Ga i/o . b-arrestin1 . Ga q ) (Fig. 2, A-D) . THC evoked b-arrestin1-, Ga q -, and Gbg-biased signaling compared with Ga i/o , in both (Fig. 2, A-D) .
Each cannabinoid analyzed here displayed unique functional selectivity for different signaling pathways. Overall, the bias factor of 2-AG and AEA was shifted toward Ga i/odependent ERK phosphorylation, and the bias factor of THC1CBD was shifted away from Ga i/o -dependent ERK phosphorylation, in STHdh Q111/Q111 cells. The reduced pERK E max in mHtt-expressing STHdh Q111/Q111 cells compared with STHdh Q7/Q7 cells (Table 1) may result from lower CB 1 levels (50%) ). An important advantage of using the operational model to estimate the relative activity and ligand bias is that this model negates the effects of differences in receptor density (Kenakin et al., 2012) . Therefore, differences in bias between STHdh Q7/Q7 and STHdh Q111/Q111 cells were probably mHtt-dependent and not the result of changes in agonist potency or efficacy. Cannabinoid-Specific Changes in Cellular Function and Viability. Treatment of STHdh Q7/Q7 cells with WIN, 2-AG, AEA, or THC resulted in a small increase in ATP, whereas treatment with CP, CBD, or THC1CBD resulted in a decrease in ATP (Fig. 3A) . In STHdh Q111/Q111 cells, basal ATP levels were approximately 50% lower than basal ATP levels in STHdh Q7/Q7 cells. ATP levels increased in STHdh Q111/Q111 cells treated with WIN, 2-AG, AEA, or THC and decreased with CP or CBD (Fig. 3E ). THC1CBD treatment resulted in higher ATP levels in STHdh Q111/Q111 cells. CP and CBD were the only cannabinoids tested that evoked Ga S -biased (CREB) signaling in STHdh cells. The lower ATP levels observed in cells treated with CP or CBD may have resulted from cAMP production. However, given that cells expressing mHtt are deficient in ATP (Sadri-Vakili et al., 2006; Laprairie et al., 2013) , cannabinoids that exaggerate this state may exacerbate cellular pathology.
Excessive glutamate release from cortical neurons and GABA release from striatal medium spiny projection neurons are both observed in HD (Benn et al., 2007; Botelho et al., 2014) . Compounds that limit neurotransmitter release may, therefore, be beneficial in HD, whereas compounds that enhance neurotransmitter release may exacerbate HD pathophysiology. GABA release was inhibited by WIN, 2-AG, AEA, CP, and THC in STHdh Q7/Q7 and STHdh Q111/Q111 cells (Fig. 3 , B and F). CBD treatment was associated with enhanced GABA release in STHdh Q7/Q7 and STHdh Q111/Q111 cells and the EC 50 and E max of this response were reduced in the presence of THC (THC1CBD) (Fig. 3, B and F) . Therefore, CBD treatment may enhance excessive neurotransmitter release in HD, whereas other cannabinoids tested here limited neurotransmitter release.
Cell viability was measured by cal-AM fluorescence, which is an indicator of esterase activity and mitochondrial respiration that is positively correlated with viability, and EthD-1 fluorescence, which is an indicator of membrane permeability and cell death and therefore negatively correlated with viability (MacCoubrey et al., 1990) . Basal cal-AM fluorescence (% esterase activity) was 60% less in STHdh Q111/Q111 cells compared with STHdh Q7/Q7 cells (Fig. 3, C and G) . Cal-AM fluorescence was decreased by 40% in STHdh Q7/Q7 and STHdh Q111/Q111 cells treated with CP or THC and increased by 40% in STHdh Q111/Q111 cells treated with WIN, 2-AG, AEA, or CBD (Fig. 3, C and G) . Basal EthD-1 fluorescence (% membrane permeable cells) was 40% greater in STHdh Q111/Q111 cells compared with STHdh Q7/Q7 cells (Fig. 3, D and H) . EthD-1 fluorescence was increased by 30% in STHdh Q7/Q7 and STHdh Q111/Q111 cells treated with CP or THC (Fig. 3, D  and H) . EthD-1 fluorescence was decreased by 20% in AEAand CBD-treated STHdh Q7/Q7 cells, and by 40% in WIN-, 2-AG-, AEA-, and CBD-treated STHdh Q111/Q111 cells (Fig. 3, D and H) . The effect of CBD predominated over that of THC for both cal-AM and EthD-1 fluorescence in both cell lines. Therefore, in these viability assays, the CP and THC (which both displayed b-arrestin1 bias) appeared harmful, whereas other cannabinoids improved viability in STHdh Q111/Q111 cells. Functional CB 1 residing at the plasma membrane undergo internalization following ligand binding and b-arrestin recruitment (Blair et al., 2009) . Total CB 1 levels were higher in WIN-, 2-AG-, and AEA-treated STHdh Q7/Q7 and STHdh
cells, compared with vehicle, whereas total CB 1 levels were lower in CP-and THC-treated STHdh Q7/Q7 and STHdh Q111/Q111 cells (Fig. 4A) . The fraction of CB 1 at the and STHdh Q111/Q111 cells treated with various cannabinoids for 12 hours (Fig. 4, A and B) . The fraction of CB 1 at the plasma membrane was lower in WIN-, 2-AG-, CP-, and THC-treated cells, and higher in CBD-treated cells (Fig. 4B) . CP and THCand to a lesser extent WIN and 2-AG-displayed greater b-arrestin1 bias than AEA or CBD. The mechanism of cannabinoid-dependent induction of CB 1 expression has been described previously . Here, it is important to note that treatment with cannabinoids that evoked Ga i/o -and Gbg-biased signaling (2-AG, AEA) was associated with higher CB 1 levels, whereas treatment with CP and THC (b-arrestin1-biased cannabinoids) was associated with lower CB 1 levels, suggesting that cannabinoids that are functionally selective for b-arrestin1 may reduce the available pool of CB 1 receptors. The effects of THC and CBD were neutralized by one another (Fig. 4, A and B) .
Mechanism of CP-and CBD-Dependent Ga S Signaling. CBD is known to modulate the activity of many cellular GPCRs, including CB 1 , the type 2 cannabinoid receptor (CB 2 ) (Hayakawa et al., 2008) , the serotonin 5HT 1A receptor (Russo et al., 2005) , G protein-coupled receptor 55 (Ryberg et al., 2007) , and the m-and d-opioid receptors (Kathmann et al., 2006) . Here, CBD treatment resulted in CB 1 -independent CREB phosphorylation (Fig. 5) . CREB phosphorylation was highest 30 minutes after CBD treatment and was sustained for the duration of the experiment (60 minutes) (Fig. 5A) . Treatment of STHdh Q7/Q7 cells with the 5HT 1A agonist 8-OH-DPAT resulted in a dose-dependent increase in CREB phosphorylation that was competitively inhibited by the 5HT 1A antagonist WAY-100,635 and CBD (Fig. 5B) . Treatment of STHdh Q7/Q7 cells with CBD alone also resulted in a dosedependent increase in CREB phosphorylation, with less potency and efficacy that the full agonist 8-OH-DPAT (Fig. 5C ). CBD-dependent CREB phosphorylation was not inhibited by the CB 1 antagonist O-2050, but was inhibited by WAY-100,635 (Fig. 5C ), indicating that CBD activated CREB via 5HT 1A . It is not known whether the partial agonism of 5HT 1A by CBD is functionally antagonistic of serotonergic signaling in vivo and whether this would play a role in CBD-based treatments of neurologic disorders.
Unexpectedly, we observed a switch in signaling following continued drug exposure for CP. At 10 minutes CP treatment produced Ga i/o -dependent ERK phosphorylation that returned to basal levels by 25 minutes; and at 30 minutes CP treatment produced Ga s -dependent CREB phosphorylation (Fig. 5A ). STHdh cells endogenously express the type 2 dopamine receptor (D 2 ) (Paoletti et al., 2008) and heterodimerization of CB 1 and D 2 is known to lead to a switch in coupling from Ga i/o to Ga s following treatment with CP (Glass and Felder, 1997; Kearn et al., 2005) . Therefore, we hypothesized that CP could be functionally selective for CB 1 /D 2 heterodimer signaling to explain the switch from Ga i/o to Ga s . Cotreatment of STHdh Q7/Q7 cells with CP and 1 mM quinpirole (a D 2 agonist) shifted the concentration-response curve for CREB phosphorylation right, as did cotreatment with O-2050 (a competitive antagonist of CB 1 ), whereas cotreatment with 10 mM haloperidol (a D 2 antagonist) shifted the concentration-response curve left (Fig. 5D ). Quinpirole and haloperidol did not effect CREB phosphorylation alone (Fig. 5D) . From these data, we suggest that CP selectively enhanced either physical heterodimerization between CB 1 /D 2 
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or functional signaling through these receptors with a subsequent switch from Ga i/o to Ga s (Kearn et al., 2005) .
Discussion
Correlations between Functional Selectivity and Cellular Viability. In this study, we described the biased signaling properties of six cannabinoids in the STHdh cell culture model of striatal medium spiny projection neurons. System bias shifted toward Ga i/o for 2-AG and AEA in STHdh Q111/Q111 (mHtt-expressing) cells compared with STHdh Q7/Q7 cells. Treatment of STHdh Q111/Q111 cells with cannabinoids that signaled via CB 1 and were functionally selective for Ga i/o and Gbg (2-AG, AEA) was associated with the greatest improvement in ATP production, inhibition of GABA release, cellular metabolic activity (esterase activity), and cell death (membrane permeability). In contrast, ligands that preferentially enhanced b-arrestin1-recruitment (THC and CP) reduced cellular viability in both STHdh Q7/Q7 and STHdh Q111/Q111 cells as determined by the same measures. We have previously observed that derivatives of AEA normalize CB 1 levels in STHdh Q111/Q111 cells via Ga i/o , Gbg, Akt, and nuclear factor (NF)-kB, and that normalization of CB 1 was associated with improved cell function and viability (Laprairie et al., , 2014 . Recently, three studies have demonstrated that increasing CB 1 levels in medium spiny projection neurons in the R6/2 mouse model of HD via adenovirus-mediated overexpression normalizes brain-derived neurotrophic factor levels, reduces striatal atrophy, and prevents decreases in dendritic spine density and levels of excitatory synaptic markers, such as synaptophysin and vesicular glutamate transporter, but does not improve deficits in motor coordination (Chiarlone et al., 2014; Naydenov et al., 2014; Blázquez et al., 2015) . In accordance with this, knockdown or knockout of CB 1 in medium spiny projection neurons of R6/2, N171-82Q, or Hdh Q150/Q150 HD mice further reduces the pool of CB 1 and exacerbates deficits in motor control, enhances striatal atrophy, and reduces survival (Blázquez et al., 2011; Mievis et al., 2011; Horne et al., 2013) . Further, individuals with HD and a variant of the CB 1 gene (CNR1 rs4707436) that is associated with lower levels of CB 1 begin displaying motor-related symptoms of HD earlier than individuals with HD and normal CNR1 (Kloster et al., 2013) . Together, these studies and our [ATP] was determined using the CellTiter Glo assay (Promega).
[GABA] in cell culture media was determined using GABA enzyme-linked immunosorbent assay (Novatein Bio, Woburn MA). % Cellular esterase activity (calcein-AM cleavage) and % membrane permeable cells (ethidium homodimer-1 penetration) were determined using the Live/Dead cytotoxicity assay (Invitrogen/ThermoFisher Scientific, Grand Island, NY). Concentration-response curves were fit using nonlinear regression models. N = 4. Fig. 4 . Long-term exposure to cannabinoids affected CB 1 localization and levels. STHdh Q7/Q7 and STHdh Q111/Q111 cells were treated with 1.0 mM 2-AG, AEA, WIN, CP, THC, CBD, or THC+CBD (1:1) for 12 hours, and total CB 1 levels (A) and the fraction of CB 1 at the plasma membrane (B). (A) Total CB 1 levels were determined using In-Cell Western and expressed relative to b-actin levels. N = 8. (B) The fraction of CB 1 at the plasma membrane was determined using On-and In-Cell Western. N = 8. *P , 0.01 compared with vehicle-treated cells within cell type, †P , 0.01 compared with STHdh Q7/Q7 cells within treatment group, as determined using two-way ANOVA followed by Bonferroni post-hoc analysis. data provide support for Ga i/o -and Gbg-selective activation of CB 1 to maintain CB 1 levels and the cellular function and viability of cells expressing mHtt (Blázquez et al., 2011 (Blázquez et al., , 2015 Mievis et al., 2011; Horne et al., 2013; Chiarlone et al., 2014; Naydenov et al., 2014) .
Use of THC and CBD in HD. Despite a lack of clinical evidence, patients suffering from HD may be seeking medical marijuana or acquiring it from other sources in an attempt to relieve some of the symptoms of their disease (Müller-Vahl et al., 1999; Meisel and Friedman, 2012; Koppel et al., 2014) . Most medically available and tested illicit marijuana contains a high concentration of THC relative to other cannabinoids, such as CBD (De Backer et al., 2012) . Here, we observed that THC reduced cellular function and viability in cells expressing mHtt whether THC was used alone or in a 1:1 combination with CBD. Likewise, treatment of R6/1 and R6/2 mouse models with 10 mg/kg THC is associated with worsening of HD signs and symptoms (Dowie et al., 2010) . However, others have reported improvement in motor control and reduced striatal atrophy in R6/1 and R6/2 HD treated for 6 weeks with 2 mg/kg THC beginning at 4 weeks of age (Blázquez et al., 2011) , suggesting that the deleterious effects of THC in HD are doseand time course-dependent. CBD alone displayed mixed beneficial and negative effects in STHdh Q7/Q7 and STHdh Q111/Q111 cells. CBD is known to act through a number of effectors, including as a negative allosteric modulator at CB 1 and a partial agonist at 5HT 1A (Pazos et al.., 2013; Laprairie et al., 2015) . It is unclear which effects of CBD predominate in vivo normally and in HD and how the combinations of any or all of the at least 65 cannabinoids found in marijuana (McPartland et al., 2015) influence one another's pharmacokinetics and pharmacodynamics Valdeolivas et al., 2012) . Further, the utility of CBD in HD remains controversial, with some studies reporting no effects in animal models and human trials (Consroe et al., 1991; Valdeolivas et al., 2012) , or positive effects in animal models (Sagredo et al., 2007 . Overall, the use of THC or marijuana may exacerbate the signs and symptoms of HD via further downregulation of CB 1 and reduced cellular viability.
Conclusions
Ga i/o -and Gbg-selective CB 1 ligands are probably the most therapeutically useful cannabinoids in the treatment of HD. However, highly potent synthetic cannabinoids, such as WIN, may produce unwanted psychoactive effects and their chronic use would probably result in receptor desensitization or downregulation (Sim-Selley and Martin, 2002; Blair et al., 2009) . Endocannabinoids, which we observed to enhance Ga i/oand Gbg-dependent signaling in the STHdh cell culture system, are rapidly metabolized in vivo and consequently have limited efficacy when they are directly administered (Devane et al.., 1992; Kondo et al., 1998) . The inhibitor of endocannabinoid catabolism URB597 has demonstrated limited efficacy at improving motor control deficits in R6/2 HD mice (Dowie et al., 2010) , but additional studies are needed to understand how elevating endocannabinoid levels affects the signs and symptoms of HD in vivo. An alternative means of enhancing endogenous CB 1 signaling is with the use of positive allosteric modulators (PAMs) of CB 1 . PAMs bind to a site on the receptor that is distinct from the site of endogenous ligand binding (i.e., the orthosteric site) and enhance the binding and efficacy of the endogenous ligands that are produced and regulated through intrinsic control mechanisms (Pamplona et al., Q7/Q7 cells were treated with 0.1-100,000 nM CP, quinpirole, or haloperidol, 6 10 mM haloperidol, 1 mM quinpirole, or 500 nM O-2050 for 30 minutes and CREB phosphorylation was measured via In-Cell Western. Concentration-response curves were fit using non-linear regression models. N = 4. All data are expressed relative to WIN E max in STHdh Q7/Q7 cells.
Biased CB1 Signaling in Huntington Disease
2012; Wootten et al., 2013) . CB 1 PAMs may increase Ga i/odependent pro-survival signaling occurring via endocannabinoids without producing the psychotropic effects associated with synthetic cannabinoid agonists, because they are unable to directly activate CB 1 . Our in vitro study of cannabinoid functional selectivity leads us to conclude that enhancement of endocannabinoid-dependent CB 1 activation may be a means of treating the signs and symptoms of HD by targeting CB 1 .
